The C-reactive protein (CRP) is an acute-phase protein produced by hepatocytes, and is a reliable marker of systemic inflammation, which is relevant to the release of the proinflammatory cytokines. The value of monitoring the CRP levels after stem cell transplantation (SCT) can identify patients at risk of treatment-related complications and mortality. Inflammatory cytokines facilitate donor T-cell activation via antigen presenting cells immediately after SCT. This study examined the relationship between the post-SCT CRP levels and a leukemic relapse. Fifty-four consecutively transplanted patients who relapsed after the allogeneic SCT were compared with nonrelapsing patients. The serum CRP levels were measured on day 0 and every 7 days thereafter until 4 weeks after the SCT. The mean CRP levels throughout the early post-SCT episode were significantly lower in the relapsing patients than in those who did not experience relapse (mean7s.e.: 26.876.3 vs 65.379.4 for first week, P ¼ 0.001; 23.973.8 vs 44.676.6 for second week, P ¼ 0.008). Univariate analysis showed that the CRP level on the first and second week, and graft-versus-host disease were significantly associated with a relapse. Multivariate analysis showed that the CRP level on the first week was the strongest independent variable predicting the risk of a relapse after SCT (P ¼ 0.04). These results indicate that the serum CRP levels early after allogeneic SCT might display the graft-versus-leukemia (GvL) effect. CRP is a surrogate of the proinflammatory cytokine release that was not measured in this study. The GvL effect appears to be efficiently strengthened by the high CRP levels that may be reflecting T-cell activation.
Introduction
Stem cell transplantation (SCT) is a potentially curative treatment for hematological malignancies. However, the relapse of the underlying disease and graft-versus-host disease (GvHD) are major obstacles. The therapeutic potential of allogeneic SCT relies on the graft-versusleukemia (GvL) effect, which eradicates the residual malignant cells via immunological mechanisms. 1 Beneficial GvL effects are related to the toxicity of GvHD. With the introduction of a better immunosuppressive treatment and improved supportive care, the occurrence of GvHD and its associated infections have decreased 2 but leukemia relapse is still an important cause of treatment failure. 3 The C-reactive protein (CRP) is an acute phase protein that is produced by the liver and is a reliable marker of systemic inflammation. 4 The proinflammatory cytokines are overproduced in response to total body irradiation (TBI) and/or high-dose chemotherapy, which facilitate T-cell activation either directly or indirectly by upregulating the adhesion and costimulation molecules on antigen presenting cells. 5 In marrow transplant recipients, the CRP levels have been reported to increase in association with the early complications including acute GvHD, hepatic venoocclusive disease (VOD) and pneumonitis. 6, 7 This study examined the relationship between the post-SCT CRP levels and leukemic relapse. The mean CRP levels throughout the early post-SCT episode were found to be significantly lower in the relapsing patients than in those who did not experience relapse. The degree of systemic inflammation, as reflected by the serum CRP levels, during the early period following SCT, might correlate with the GvL effect, even if it is associated with an increase in the overall transplant-related mortality.
Patients and methods
Patients and transplant condition A total of 108 adult patients who underwent allogeneic SCT in our institute were analyzed retrospectively. Among them, a series of 54 consecutive patients who underwent SCT from February 1999 to September 2004 and subsequently relapsed within 36 months following SCT were examined (relapse group). For comparison, an equal number of pair mates were selected; 54 consecutive patients from January 2001 to April 2002 receiving an allogeneic SCT with no relapse as of May 2005 (remission group). The nonrelapsing group was chosen to have an equal or longer follow-up time than paired patients with relapse by assuming that the relapse event ends the follow-up for each patient in the relapse group. The non-relapsing patients had follow-up (X36 months) longer than those with a relapse.
There were 60 male and 48 female subjects with a median age of 37 years (range 17-53). The disease status at the time of the transplant is as follows: AML (first or second remission: n ¼ 42, incomplete remission: n ¼ 8), ALL (first or second remission: n ¼ 30, incomplete remission: n ¼ 4), and CML in the first chronic phase (n ¼ 24). Patients with acute leukemia in remission and CML in the first chronic phase were considered to be in the early disease state, representing 90.7% of cases. The marrow was the source of stem cells in most cases (94.4%), and the donors were human leukocyte antigen (HLA)-identical siblings (n ¼ 89) or volunteer-unrelated donors (n ¼ 19). All the patients received standard supportive care including isolation in laminar flow rooms, treatment of empirical broad-spectrum antibiotics in the case of fever, and weekly high-dose immunoglobulin therapy. The patients at high risk of developing hepatic VOD, such as those with a pretransplantation liver disturbance, pretransplantation abdominal irradiation, or a HBV infection received low-dose heparin (100 U/kg daily) to prevent VOD. 8 Granulocyte colonystimulating factor was administered to all patients 7 days after the marrow infusion until stable neutrophil recovery, which is defined as the achievement of stable neutrophil levels 41.0 Â 10 9 /l. Among the 54 relapsing patients, 48 developed a hematological relapse and six cytogenetic relapse. In acute leukemia, relapse was defined as blasts accounting for more than 5% of the nucleated cells in the bone marrow. In CML, hematological relapse was defined as peripheral blood leukocytosis with a hypercellular marrow and Philadelphia chromosome (Ph) positivity on cytogenetic analysis. The cytogenetic relapse of CML was considered present if one or more Ph þ metaphase was detected without any evidence of hematological relapse. 9 CRP measurement Serum CRP samples were taken during all 108 post-SCT episodes, every 7 days from the day of SCT until 4 weeks after SCT. The CRP levels were measured using a Behring nephelometer analyzer (normalp3 mg/l).
Definition of major complications
Acute GvHD was graded on a four-point scale (I indicated mild disease, and IV severe disease) [10] [11] [12] and chronic GvHD was classified as being either limited or extensive, as previously described. 13, 14 GvHD was designated acute or chronic based on the clinical picture rather than on a 100-day period. 15 Skin, rectum, or liver biopsies were performed when indicated to confirm GvHD. Cyclosporin or tacrolimus was infused from day À1 for 24 h, and was kept at the target level of 200-400 or 5-15 ng/ml, respectively until marrow engraftment. The dose was then varied according to the symptoms of GvHD. Fever of an unknown origin was defined as a body temperature X38.31C for at least 2 consecutive days. Hepatic VOD was diagnosed according to the presence of hyperbilirubinemia (43.0 mg/dl), weight gain (o2.5% of initial weight) and right upper quadrant pain with or without the presence of hepatomegaly. 16 Cytomegalovirus (CMV) antigenemia was diagnosed as immunohistochemical staining, using the monoclonal antibodies against the CMV pp65 protein. Antigenemiaguided, risk-adapted preemptive therapy was performed with the aim of preventing CMV disease. 17 
Statistical analysis
Differences in the means of continuous measurements were tested with the use of Student's T test and checked with the use of the Mann-Whitney test. The association between the categorical variables was investigated using a w 2 or Fisher's exact test. Factors of interest were compared between patient groups. Kaplan-Meier curves for the probability of relapse were plotted and compared with the use of the log-rank test. Preliminary univariate analyses were used to identify factors that could be used to build Cox proportional hazard regression model for the probability of relapse. Table 1 shows the characteristics of the two distinct patient groups. The relapse and remission groups were comparable with the respect to the pre-transplant variables that are known to potentially affect relapse. There were no significant differences in age, gender, transplant type, the underlying disease, conditioning regimen, GvHD prophylaxis, time (days) from SCT to an absolute neutrophil count 4500/ml and to a platelet count 420 000/ml and the stem cell source. The incidence of post transplant complications such as fever, hepatic VOD, hemorrhagic cystitis, and CMV infection were similar in the two groups. However, the relapse group patients had a lower incidence of chronic GvHD than the remission group (P ¼ 0.029).
Results

Clinical data
Relapse and CRP patterns Figure 1 shows a comparison of the CRP patterns obtained in both the relapse and remission groups. The mean CRP levels of the early post-SCT episode (during the initial 2 weeks) were significantly lower in the relapsing patients than in those who did not experience a relapse (the mean7s.e., 26.876.3 vs 65.379.4 for first week, P ¼ 0.001; 23.973.8 vs 44.676.6 for second week, P ¼ 0.008). There was no significant difference between the mean CRP levels in the relapse and remission groups on the third and fourth week after the SCT (the mean7s.e., 14.972.6 vs 18.872.8 for third week, P ¼ 0.301; 6.070.9 vs 9. 671.7 for fourth week, P ¼ 0.059).
Several factors, which were considered to influence the outcome after SCT, were tested together with the early post-SCT CRP levels to determine if they increased the risk of developing a relapse. These factors included age, gender, disease type and the status at the time of SCT, the conditioning regimen, the graft type, GvHD prophylaxis, fever, GvHD occurrence and other transplant complications such as VOD, hemorrhagic cystitis, and CMV infection. Table 2 shows the results of univariate analysis using the appropriate statistical tests. The mean CRP levels in the initial 2 weeks, chronic GvHD or acute þ chronic GvHD were found to be associated with the occurrence of leukemia relapse. Multivariate analysis was also performed with the same factors using Cox regression model. The serum CRP level on the first week after SCT was identified to be the most powerful independent variable (P ¼ 0.04) and appeared to be a reliable parameter for assessing the risk for a patient developing relapse. The presence of acute þ chronic GvHD exhibited a marginally significant impact on relapse (P ¼ 0.062).
Furthermore, the 1-year probability of relapse in patients who had the low median CRP (o17 mg/l) on the first week was 46.875.7% as compared to 28.276.2% for those showing high levels (the median CRP of the first week X17 mg/l) (Figure 2 , P ¼ 0.0037). When the group was split into patients within 2s.d. of normal range and those with higher levels, the relapse rate was significantly different between the two groups (data not shown). The relationship between the maximum CRP levels (CRPmax) and a relapse was further analyzed. The remission group had a mean7s.e. CRPmax of 77.879.2 mg/l, whereas the relapse group was 37.276.3 mg/l (Po0.001) (Figure 3 ). 
Clinical events and CRP patterns
The changes in the CRP levels were compared between the two groups with different treatment-related morbidities including acute or chronic GvHD, fever and the other major transplant-related complications. 7 The mean CRP levels of the first and second weeks were significantly higher in those patients with acute and chronic GvHD than in those without GvHD (Figure 4a Figure 1 Mean CRP levels during the post-SCT period of the patients who relapsed were compared with those who maintained remission. The CRP levels on the first and second week were significantly lower in the patients who relapsed ( w P ¼ 0.001 and z P ¼ 0.008, respectively). Figure 4 The mean CRP7s.e. levels after an allogeneic SCT, the diamonds show the patients with transplant-related events and the circles the patients without the events, (a) acute GvHD Xgrade II and chronic GvHD, (b) the transplant-related complications including fever, hepatic VOD or hemorrhagic cystitis ( w Po 0.001; z Po0.05).
72.3713.3 vs 35.776.0 for first week, P ¼ 0.009; 57.7710.0 vs 24.873.2 for second week, Po0.001). However, there were no significant differences between the patients with or without GvHD with regard to the CRP levels of the third and fourth weeks (Figure 4a ; the mean7s.e., 19.873.8 vs 15.772.2 for third week, P ¼ 0.34; 9.172.1 vs 7.270.9 for 4th week, P ¼ 0.37). Patients who had the post-SCT complications including fever, hepatic VOD or hemorrhagic cystitis showed a marked increase in the CRP levels ( Figure 4b ; the mean7s.e., 67.979.4 vs 22.475.3 for first week, Po0.001; 47.376.2 vs 19.573.8 for second week, Po0.001; 23.373.2 vs 9.871.5 for third week, Po0.001; 9.971.5 vs 5.270.8 for fourth week, P ¼ 0.017). It was found that the CRPmax was also significantly higher in those patients with acute þ chronic GvHD, fever and the other transplant-related complications (data not shown).
Discussion
This study compared the weekly serum CRP levels after an allogeneic SCT between a relapse cohort of adult patients with leukemia who were consecutively allografted during 5 years and a remission cohort who maintained remission for 3 years or more after the allogeneic SCT. Their pre-transplant variables, which might be relevant to relapse, were comparable. These results demonstrate that the CRP levels early after SCT as well as the development of chronic GvHD were the main determinants for the occurrence of a post transplant relapse presumably because high levels of proinflammatory cytokines appeared to prime and activate the donor T cells more efficiently, potentiating the GvL effect. Although the underlying pathophysiological mechanisms are not clear, the identification of a new biomarker able to predict relapse after allogeneic SCT is of high interest. In addition, the relationship between the CRP levels and the occurrence of major complications following allogeneic SCT was confirmed.
There are at least two major components of successful allogeneic SCT for the treatment of leukemia. First, the conditioning regimen results in major cytoreduction of the leukemia and the destruction of the marrow and immune system. However, this therapy kills cells via first-order kinetics and is unlikely to kill all tumor cells. Increasing its intensity reduces the relapse rate but substantially increases the treatment-related morbidity and mortality. 18 Therefore, it is difficult to enhance the level of malignant cell death by augmenting the conditioning regimen. It is known that a second component associated with the donor graft itself contributes to the antileukemic properties of allogeneic SCT. This immunological component, which is referred to as the GVL effect, appears to be mediated by the immunocompetent donor leukocytes contained in the allogeneic graft. The donor T cells are infused into a patient who has been profoundly damaged by the underlying disease, infection, and conditioning, all of which result in substantial proinflammatory changes in the endothelial and epithelial cells. The activated host cells then secrete inflammatory cytokines, such as TNF-a and IL-1. 19 The presence of inflammatory cytokines during this phase upregulates the adhesion molecules, costimulatory molecules, and major histocompatibility complex antigens. [20] [21] [22] [23] Such a 'danger signal' expressed by the injured host tissues is essential for the activation of host dendritic cells (DCs), which is necessary for initiating the primary and secondary immune responses. 24 In this patient cohort, the serum CRP levels during the early 2 weeks after a SCT were associated with the subsequent occurrence of leukemia relapse after allogeneic SCT. In particular, the CRP levels on the first week were the strongest independent variable to be associated with a relapse. In the absence of inflammation, the DCs do not become fully activated and induce tolerance rather than immunity. 25, 26 Attenuation of the inflammatory cytokine secretions might be one of the potential mechanisms for tumor escape after allogeneic SCT. The individual patient's inflammatory response, as evaluated by the serum CRP levels, during the early post transplant period might determine the activation of T lymphocytes, which play a role in preventing leukemia relapse. Some evidence from a murine study suggests that the downregulation of post transplant antihost alloreactivity is temporally associated with the time of relapse. 27 The release of serum CRP has been reported in neutropenic patients with bacteremia. 28 However, bacteremia is not the main trigger for early CRP release in patients undergoing SCT because it occurred in similar patients with post transplant complications. These results are consistent with the reports 6, 7 showing that the patients with high CRP levels proved to be useful for identifying those patients who develop acute and/or chronic GvHD as well as other complications. Our results strongly suggest that the early rise in CRP is a surrogate for acute and/or chronic GvHD which themselves are powerful predictors of relapse. 29 The background of interindividual differences in CRP level may be related to polymorphisms in CRP gene 30, 31 and genetic variations in components governing the inflammatory response. IL-1 and IL-6 are the central regulators of the acute phase proteins. Several variations in the IL-1 gene cluster and the IL-6 gene correlate with the expression of these interleukins, and they have also been associated with a number of inflammatory diseases. 32 More recently, it was shown that the serum IL-6 levels may be an early predictor of transplant-related complications and might trigger both pro-and anti-inflammatory cytokine release. 33 In summary, antigen-activated T cells are responsible for leukemia control, graft rejection, GvHD, and protection from infectious agents. The procurement of the inflammatory status, as reflected by the higher serum CRP levels, allowed the antigen-activated donor T cells to maintain their anti-leukemic effects, whereas the suppression of proinflammatory cytokines might interfere with the GvL effects. The early rise of CRP may be a surrogate for GvL effect as well as GvHD. Pre-emptive therapy and the use of a combination of several anticytokines, an anticytokine receptor or anticytokines with other forms of immunotherapy should be used with caution particularly in patients at high risk of relapsing after allogeneic SCT.
